Promoter Bank clone, Human prostate-specific antigen/kallikrein 3 (PSA/KLK3) promoter
Alternative name | p1879-8F |
---|---|
Clone info. | PCR amplified human prostate-specific antigen/kallikrein 3 (PSA/KLK3) promoter sequence was inserted into a Renilla luciferase reporter vector pKM2L (RDB04026). |
Comment | PCR cloning, forward primer, G1PB0007F: 5' gaattccacattgtttgctgc 3'; reverse primer, G1PB0007R: 5' tggggctggggagcctccccc 3'; Cloned fragment: 50854283 to 50854921(NC_000019.10); relatively -632 to +7, where +1 corresponds to 1 nt of NM_001648.2. Entire sequence of promoter region has not been confirmed. Known differences: C to T substitution at 50,854,560; G to A substitution at 50,854,631. Promoter activity has not been analyzed. |
Vector backbone | pKM2L (RDB04026) (Plasmid) |
Size of vector backbone | 4.2 kb |
Selectable markers | Kan^r |
Gene/insert name | Human kallikrein-related peptidase 3 genomic DNA |
Depositor|Developer | DNA Bank, | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms | Order form [Credit Card Payment ![]() ![]() ![]() MTA, for use for not-for-profit academic purpose [Word ![]() ![]() Please visit Information of Request for Distribution.[link] |
---|---|
Terms and conditions for distribution | 1. The RECIPIENT agrees to use the BIOLOGICAL RESOURCE only for academic research in the non-profit organization. 2. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation. |
必要書類 | 提供依頼書 ![]() ![]() 提供同意書 (MTA, 非営利学術目的用)[Word ![]() ![]() 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
---|---|
MTAに書く使用条件 | 1. 本件リソースは学術研究機関にのみ提供し、学術研究にのみ利用することができる。 2. 謝辞の表明を必要とする。 MTAに書く付加的使用条件: 本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。 |
Catalog # | Resource name | Shipping form | Fee (non-profit org.) |
---|---|---|---|
RDB05471 | pKM2L-phPSA(1) | DNA solution |
JPY 9,460 (not-for-profit academic purpose) plus cost of shipping containers, dry ice (if required) and shipping charge |
Materials & Methods section:
The pKM2L-phPSA(1) was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB05471). |
Reference section:
Further references such as user reports and related articles (go to bottom)
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
Test sheet | RDB05471_A7B9p1.pdf ![]() |
---|
Nucleotide sequence of a portion of this resource (if available).
Primer: M13_-40 Sequence file: RDB05471_A7B9a.seq ![]() |
---|
>05471_05471_A7B9_M13(-40)_G05_20_ABI24.ab1 1 CAGCGTCAGC TTGCATGCCT GCAGGTCATT TAAATAGGGA TAACAGGGTA ATGATTAAGA 61 TCTCGAGCTC TAAGCTTCAC ATATGCATGC ACTAGTGGCG AATTCCACAT TGTTTGCTGC 121 ACGTTGGATT TTGAAATGCT AGGGAACTTT GGGAGACTCA TATTTCTGGG CTAGAGGATC 181 TGTGGACCAC AAGATCTTTT TATGATGACA GTAGCAATGT ATCTGTGGAG CTGGATTCTG 241 GGTTGGGAGT GCAAGGAAAA GAATGTACTA AATGCCAAGA CATCTATTTC AGGAGCATGA 301 GGAATAAAAG TTCTAGTTTC TGGTCTCAGA GTGGTGCAGG GATCAGGGAG TCTCACAATC 361 TCCTGAGTGC TGGTGTTTTA GGGCACACTG GGTCTTGGAG TGCAAAGGAT CTAGGCACGT 421 GAGGCTTTGT ATGAAGAATC GGGGATCATA CCCACCCCCT GTTTCTGTTT CATCCTGGGC 481 GTGTCTCCTC TGCCTTTGTC CCCTAGATGA AGTCTCCATG AGCTACAGGG CCTGGTGCAT 541 CCAGGGTGAT CTAGTAATTG CAGAACAGCA AGTGCTAGCT CTCCCTCCCC TTCCACAGCT 601 CTGGGTGTGG GAGGGGGTTG TCCAGCCTCC AGCAGCATGG GGAGGGCCTT GGTCAGCCTC 661 TGGGTGCCAG CAGGGCAGGG GCGGAGTCCT GGGGAATGAA GGTTTTATAG GGCTCCTGGG 721 GGAGGCTCCC CAGCCCCGCC TGTCGACGCG TAGAATTCAC CCGGGTACTG CAGAAGTTGG 781 TCGTGAGGCA CTGGGCAGGT AAGTATCAAG GTTACAAGAC AGGTTTAAGG AGACCAATAG 841 AAACTGGGCT TGTCGAGACA GAGAAGACTC TTGCGTTTCT GATAGGCACC TATTGGTCTT 901 ACTGACATCC ACTTTGCCTT TCTCTCCACA GGTGTCCACT CCCAGTTCAA TTACAGCTCT 961 TAACGCTAGA GTACTTAAAT ACGACTCACT ATAGCTAGCC ACCATGGGCT TCCCAAGTGT 1021 ACGACCCCCG AGCAACGCAA ACGCATGGAT CACTTGGTCC TTCAGTGGAT GGCTTCGCTT 1081 GCCAAGGCAA ATGAATCGGT TGCCTTGA // |
Primer: phRLR2 Sequence file: RDB05471_A7B9b.seq ![]() |
>05471_05471_A7B9_phRLR2_H05_23_ABI24.ab1 1 ACCTTGCCTG TCTCGACAGC CCAGTTTCTA TTGGTCTCCT TAAACCTGTC TTGTAACCTT 61 GATACTTACC TGCCCAGTGC CTCACGACCA ACTTCTGCAG TACCCGGGTG AATTCTACGC 121 GTCGACAGGC GGGGCTGGGG AGCCTCCCCC AGGAGCCCTA TAAAACCTTC ATTCCCCAGG 181 ACTCCGCCCC TGCCCTGCTG GCACCCAGAG GCTGACCAAG GCCCTCCCCA TGCTGCTGGA 241 GGCTGGACAA CCCCCTCCCA CACCCAGAGC TGTGGAAGGG GAGGGAGAGC TAGCACTTGC 301 TGTTCTGCAA TTACTAGATC ACCCTGGATG CACCAGGCCC TGTAGCTCAT GGAGACTTCA 361 TCTAGGGGAC AAAGGCAGAG GAGACACGCC CAGGATGAAA CAGAAACAGG GGGTGGGTAT 421 GATCCCCGAT TCTTCATACA AAGCCTCACG TGCCTAGATC CTTTGCACTC CAAGACCCAG 481 TGTGCCCTAA AACACCAGCA CTCAGGAGAT TGTGAGACTC CCTGATCCCT GCACCACTCT 541 GAGACCAGAA ACTAGAACTT TTATTCCTCA TGCTCCTGAA ATAGATGTCT TGGCATTTAG 601 TACATTCTTT TCCTTGCACT CCCAACCCAG AATCCAGCTC CACAGATACA TTGCTACTGT 661 CATCATAAAA AGATCTTGTG GTCCACAGAT CCTCTAGCCC AGAAATATGA GTCTCCCAAA 721 GTTCCCTAGC ATTTCAAAAT CCAACGTGCA GCAAACAATG TGGAATTCGC CACTAGTGCA 781 TGCATATGTG AAGCTTAGAG CTCGAGATCT TAATCATTAC CCTGTTATCC CTATTTAAAT 841 GACCTGCAGG CATGCAAGCT TGGCACTGGC CGTCGTTTTA CAACGTCGTG ACTGGGAAAA 901 CCCTGGCGTT ACCCAACTTA ATCGCCCTTG CAGCACATCC CCCTTTCGCC AGCTGGCGTA 961 AATAGCGAGA GGCCCGCACC CGATCGCCCT TTCCCACAGT TTGCGCAGCC CTGAAATGGC 1021 GAAATGCGAT TATTCACAAA GCCGCCGTTC CCGTCCAGGT CAGCGTAATG CTCTGCCAGT 1081 GTACGATCGA ATAAGCGAGT TCTGAATTTA GCAGAAC // |
Primer: pAxCALNL_F1 Sequence file: RDB05471_A7B9c.seq ![]() |
>05471_05471_A7B9_pAxCALNL_F1_A06_03_ABI24.ab1 1 ACATCTATCT TATCATGTCT GCTCGAAGCG GCCGCTCTAG AATTACTGCT CGTTCTTCAG 61 CACGCGCTCC ACGAAGCTCT TGATGTACTT ACCCATTTCA TCTGGAGCGT CCTCCTGGCT 121 GAAGTGGAGG CCCTTCACCT TCACGAACTC GGTGTTAGGG AACTTCTTAG CTCCCTCGAC 181 AATAGCGTTG GAAAAGAACC CAGGGTCGGA CTCGATGAAC ATCTTAGGCA GATCGTCGCT 241 GGCCCGAAGG TAGGCGTTGT AGTTGCGGAC AATCTGGACG ACGTCGGGCT TGCCTCCCTT 301 AACGAGAGGG ATCTCGCGAG GCCAGGAGAG GGTAGGCCGT CTAACCTCGC CCTTCTCCTT 361 GAATGGCTCC AGGTAGGCAG CGAACTCCTC AGGCTCCAGT TTCCGCATGA TCTTGCTTGG 421 GAGCATGGTC TCGACGAAGA AGTTATTCTC AAGCACCATT TTCTCGCCCT CTTCGCTCTT 481 GATCAGGGCG ATATCCTCCT CGATGTCAGG CCACTCGTCC CAGGACTCGA TCACGTCCAC 541 GACACTCTCA GCATGGACGA TGGCCTTGAT CTTGTCTTGG TGCTCGTAGG AGTAGTGAAA 601 GGCCAGACAA GCCCCCCAGT CGTGGCCCAC AAAGATGATT TTCTTTGGAA GGTTCAGCAG 661 CTCGAACCAA GCGGTGAGGT ACTTGTAGTG ATCCAGGAGG CGATATGAGC CATTCCCGCT 721 CTTGCCGGAC TTACCCATTC CGATCAGATC AGGGATGATG CATCTAGCCA CGGGCTCGAT 781 GTGAGGCACG ACGTGCCTCC ACAGGTAGCT GGAGGCAGCG TTACCATGCA GAAAAATCAC 841 GGCGTTCTCG GCGTGCTTCT CGGAATCATA GTAGTTGATG AAGGAGTCCA GCACGTTCAT 901 TTGCTTGCAG CGAGCCCACC ACTGAGGCCC AGTGATCATG CGTTTGCGTT GCTCGGGGGT 961 CGTACACCCT TGGAAGCCAT GGTGGCTAGC CTATAGTGAG TCGTATTTAA GGTACTCTAG 1021 CCCTTTAGAG CTGTAAATTG AAACTGGGAA GTTGACACCT TGTGGGAGAA GAAGGCCAAG 1081 TGCATGGTCA GGTTAGAACC CAATAGGTGT GCCTTAATCC // |
Please visit Sequencing and PCR primers for primer information.
Original, user report and related articles
Featured content